[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"severe-dengue\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:severe-dengue":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,81],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100487770","efficacy-of-dengue-infection-with-warning-signs-treated-with-dexamethasone-dengdex-study-100487770",false,"NCT05631405","Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone (DengDex Study)","Efficacy of Dengue Infection With Warning Signs Treated With Dexamethasone","Inclusion Criteria:\n\n* Laboratory confirmed Dengue infected patients (Positive NS1 Ag or anti-DENV IgM by Dengue Duo test)\n* And still in febrile phase (Body temp\\>37.5 C)\n* Shock : Sys\\\u003C90mmHg or Narrow PP (\\\u003C20mmHg) orTachycardia (pulse\\>100\u002Fmin) with Hematocrit decreased ≥20 %\n* Fluid accumulation and respiratory distress\n* Severe bleeding\n* Severe organ involvement\n\nExclusion Criteria:\n\n* Severe dengue\\> 24 hrs\n* Dengue without warning signs\n* Pregnancy\n* Patient who receieved any steroid within 1 week","ALL","7 Years","99 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this randomized double-blinded placebo-controlled trial is to learn about dexamethasone and the treatment of severe dengue population. The main question it aims to answer are steroid therapy may be effective in dengue.",[27],"Severe Dengue",[27,29,30],"Dexamethasone","Steroid","RECRUITING","2026-06-15",{"date":34,"type":35},"2026-06-16","ACTUAL",{"date":37,"type":35},"2022-10-16",{"date":39,"type":21},"2027-12-31",{"name":41,"class":42},"Chulalongkorn University","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100634728","phase-3-therapeutics-for-moderate-and-severe-dengue-100634728","NCT07543458","Therapeutics for Moderate and Severe Dengue","A Randomised Platform Trial to Evaluate Therapeutics in Patients With Moderate or Severe Dengue (DEN-HOST)","DEN-HOST","Inclusion Criteria:\n\n* Age ≥5 years\n* Decision to hospitalise\n* Clinical diagnosis of dengue\n* Participants must also have at least one of the following:\n\n  1. Severe abdominal pain or tenderness\n  2. Vomiting more than 3 times in the past 24 hours\n  3. Pleural effusion or ascites on clinical or radiological examination\n  4. Absolute haematocrit \\>50%\n  5. 15% increase in haematocrit compared with a baseline sample (defined as the first sample taken during the current illness)\n  6. Absolute platelet count \\\u003C50 × 10⁹\u002FL\n  7. Absolute platelet count \\\u003C100 × 10⁹\u002FL AND a drop \\>50 × 10⁹\u002FL in the past 32 hours\n  8. ALT or AST \\>400 IU\u002FL\n  9. Pulse pressure \\\u003C20mmHg or hypotension for age AND at least one of: peripheral capillary refill time \\>2 seconds; urine output 0.5ml\u002Fkg\u002Fhr; cold\u002Fclammy peripheries; agitation or altered mental state\n  10. Bleeding leading to hypotension for age or requiring blood transfusion or medical intervention (e.g. surgery, endoscopy, or vasoactive drugs)\n  11. Symptomatic bleeding into a critical site (intracranial, intraspinal, intraocular with visual impairment, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syndrome)\n  12. Requirement for organ support, including vasopressors or inotropes, assisted ventilation, dialysis or haemofiltration, or coma (unresponsive to pain without sedation) or requirement for intravenous antiseizure medications\n\nExclusion Criteria:\n\n* Patients on ≥ day 10 of illness or who are clinically improving in the opinion of the managing doctor (the 'recovery phase') will be excluded from recruitment. Other exclusion criteria are specific to individual treatment comparisons, and do not preclude randomisation to other arms of the study.\n* A participant may not enter a specific treatment comparison if that treatment is considered to be indicated or contraindicated by the responsible clinician.","5 Years",{"count":54,"type":21},8800,[56],"PHASE3","The purpose of this multi-site, factorial randomised, platform trial is to evaluate host-directed therapeutic agents in patients hospitalised with moderate and severe dengue virus infection. Our primary aim is to find safe and affordable therapeutics which prevent disease progression among those at high risk for severe dengue, and improve outcomes for those with established severe disease, thereby also reducing the substantial burden placed on health systems in dengue endemic regions.",[59,27,60,61,62,63,64,65],"Dengue","Mosquito-Borne Diseases","Vector Borne Diseases","Arbovirus Infections","Flavivirus Infections","RNA Virus Infections","Hemorrhagic Fever",[67,68,69],"dengue treatment","host-directed therapy","host-targeted therapeutics","NOT_YET_RECRUITING","2026-04-15",{"date":73,"type":35},"2026-04-21",{"date":75,"type":21},"2026-10-01",{"date":77,"type":21},"2031-07-31",{"name":79,"class":42},"Oxford University Clinical Research Unit, Vietnam",18,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":89,"sex":16,"minAge":90,"maxAge":4,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":99,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":43},"100573865","innovative-multidisciplinary-strategies-for-combating-severe-dengue-100573865","NCT06751836","Innovative Multidisciplinary Strategies for Combating Severe Dengue","Advancing Pandemic Preparedness: Innovative Multidisciplinary Strategies for COMBATing Severe Dengue","COMBAT","Inclusion Criteria:\n\nGroup 1: Dengue without warning signs Patients presenting with the following symptoms confirmed positive for dengue infection by lab diagnosis by anti-dengue IgM or NS1 ELISA will be recruited for the study under this cohort.\n\nSymptoms will be fever along with at least two of the following -\n\n* Myalgia, arthralgia\n* Nausea and\u002For vomiting\n* Rashes\n* Leukopenia Group 2: DENV with warning signs This cohort will include patients with the above symptoms and any of the following clinical signs.\n* Abdominal pain with tenderness\n* Persistent vomiting\n* Fluid accumulation\n* Mucosal bleeding\n* Restlessness, lethargy\n* Liver enlargement \\>2cm\n* Laboratory findings: An increase in hematocrit levels and a rapid decrease in platelet count Group 3: Severe dengue\n* Severe plasma leakage leads to hypovolemic shock (dengue shock syndrome) and fluid accumulation with respiratory distress.\n* Severe bleeding, such as epistaxis, internal bleeding, etc., is evaluated by a clinician.\n* Severe organ involvement with any of the following symptoms\n* Liver AST or ALT ≥ 1000\n* CNS: impaired consciousness\n* Heart and other organs failure\n\nExclusion Criteria:\n\n\\-",true,"18 Years",{"count":92,"type":21},1400,"OBSERVATIONAL","The goal of this observational study is to identify biomarkers and host factors associated with dengue severity in patients from dengue-endemic regions. The main question it aims to answer is:\n\nCan multi-omics approaches predict disease severity and identify key factors contributing to severe dengue infections?\n\nParticipants will include individuals with dengue infection, and the study will analyze their blood samples using multi-omics techniques to uncover host immune responses, disease pathogenesis, and cellular pathway interactions. The study will also assess the role of primary and secondary infections, virus serotypes, and immunological factors in disease progression. Findings aim to support disease management, improve severity prediction, and identify potential therapeutic targets to prevent severe outcomes.",[96,97,27,98],"DENV Without Warning Signs","DENV with Warning Signs","Healthy Controls Group - Age and Sex-matched",[27,100,101],"Multi-omics","Predictive biomarker","2025-02-06",{"date":104,"type":35},"2025-02-10",{"date":106,"type":35},"2025-01-03",{"date":108,"type":21},"2029-10-31",{"name":110,"class":42},"Karolinska Institutet"]